Opinion
Video
ICD-10 Impact: Desmoid Tumor Advances
Experts provide insights on recent ICD-10 code availability for desmoid tumors, its implications on diagnosis, treatment, and coverage decisions, as well as the significance for research, patient care, and health care management strategies.
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tony Phillip, MD; Mrinal Gounder, MD; Ravin Ratan, MD, MEd; and Derek van Amerongen, MD, MS.
New location-specific International Statistical Classification of Diseases, Tenth Revision (ICD-10) codes for desmoid tumors became available in October 2022 after advocacy from the Desmoid Tumor Research Foundation. These codes will enable better understanding of desmoid tumor epidemiology, facilitating research and appropriate treatments. Previously, desmoid tumors were coded vaguely under “sarcoma,” losing critical information. The new codes provide needed specificity on incidence, prevalence, geographic distribution, and outcomes. This granularity also helps communicate with payers regarding appropriate care. However, the codes’ utility relies on accurate coding, especially at smaller institutions without professional coders. Overall, the new ICD-10 codes—though requiring diligent application—should improve desmoid tumor diagnosis, treatment, research, reimbursement, and, ultimately, patient outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
